• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

膜锚定β-分泌酶抑制剂的结构设计、固相合成及对野生型和瑞典突变 APP 淀粉样蛋白生成的活性。

Structural design, solid-phase synthesis and activity of membrane-anchored β-secretase inhibitors on Aβ generation from wild-type and Swedish-mutant APP.

机构信息

Department of Psychiatry and Psychotherapy, University of Duisburg-Essen, LVR-Klinikum, Essen, Germany.

出版信息

Chemistry. 2010 Dec 27;16(48):14412-23. doi: 10.1002/chem.201002878.

DOI:10.1002/chem.201002878
PMID:21132705
Abstract

Covalent coupling of β-secretase inhibitors to a raftophilic lipid anchor via a suitable spacer by using solid-phase peptide synthesis leads to tripartite structures displaying substantially improved inhibition of cellular secretion of the β-amyloid peptide (Aβ). Herein, we describe a series of novel tripartite structures, their full characterization by NMR spectroscopy and mass spectrometry, and the analysis of their biological activity in cell-based assays. The tripartite structure concept is applicable to different pharmacophores, and the potency in terms of β-secretase inhibition can be optimized by adjusting the spacer length to achieve an optimal distance of the inhibitor from the lipid bilayer. A tripartite structure containing a transition-state mimic inhibitor was found to be less potent on Aβ generation from Swedish-mutant amyloid precursor protein (APP) than from the wild-type protein. Moreover, our observations suggest that specific variants of Aβ are generated from wild-type APP but not from Swedish-mutant APP and are resistant to β-secretase inhibition. Efficient inhibition of Aβ secretion by tripartite structures in the absence of appreciable neurotoxicity was confirmed in a primary neuronal cell culture, thus further supporting the concept.

摘要

通过固相肽合成,将β-分泌酶抑制剂通过合适的间隔物共价偶联到筏亲脂性脂质锚上,可得到显示出显著改善的细胞β-淀粉样肽 (Aβ) 分泌抑制作用的三部分结构。在此,我们描述了一系列新型三部分结构,通过 NMR 光谱和质谱对其进行了充分表征,并在基于细胞的测定中分析了它们的生物学活性。三部分结构概念适用于不同的药效团,通过调整间隔物长度来优化抑制剂与脂质双层的距离,可以优化β-分泌酶抑制的效力。含有过渡态模拟抑制剂的三部分结构在从瑞典突变型淀粉样前体蛋白 (APP) 生成 Aβ方面的效力低于从野生型蛋白生成 Aβ的效力。此外,我们的观察结果表明,特定的 Aβ变体是从野生型 APP 而不是从瑞典突变型 APP 产生的,并且对β-分泌酶抑制具有抗性。在原代神经元细胞培养物中,在没有明显神经毒性的情况下,三部分结构对 Aβ分泌的有效抑制得到了证实,从而进一步支持了这一概念。

相似文献

1
Structural design, solid-phase synthesis and activity of membrane-anchored β-secretase inhibitors on Aβ generation from wild-type and Swedish-mutant APP.膜锚定β-分泌酶抑制剂的结构设计、固相合成及对野生型和瑞典突变 APP 淀粉样蛋白生成的活性。
Chemistry. 2010 Dec 27;16(48):14412-23. doi: 10.1002/chem.201002878.
2
Purification and cloning of amyloid precursor protein beta-secretase from human brain.从人脑中纯化及克隆淀粉样前体蛋白β-分泌酶
Nature. 1999 Dec 2;402(6761):537-40. doi: 10.1038/990114.
3
Effects of huperzine A on amyloid precursor protein processing and beta-amyloid generation in human embryonic kidney 293 APP Swedish mutant cells.石杉碱甲对人胚肾293 APP瑞典突变细胞中淀粉样前体蛋白加工及β-淀粉样蛋白生成的影响。
J Neurosci Res. 2006 Sep;84(4):903-11. doi: 10.1002/jnr.20987.
4
BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.β-分泌酶1(BACE1)抑制作用可降低野生型小鼠体内内源性β-淀粉样蛋白(Aβ)水平,并改变淀粉样前体蛋白(APP)的加工过程。
J Neurochem. 2006 Dec;99(6):1555-63. doi: 10.1111/j.1471-4159.2006.04178.x. Epub 2006 Nov 2.
5
Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.口服一种强效且选择性的非肽类β-分泌酶1(BACE-1)抑制剂可在体内降低淀粉样前体蛋白的β切割及β淀粉样蛋白的生成。
J Neurochem. 2007 Feb;100(3):802-9. doi: 10.1111/j.1471-4159.2006.04260.x.
6
The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice.新型β-分泌酶抑制剂KMI-429可降低淀粉样前体蛋白转基因小鼠和野生型小鼠中β淀粉样肽的产生。
J Neurochem. 2006 Jan;96(2):533-40. doi: 10.1111/j.1471-4159.2005.03576.x. Epub 2005 Dec 8.
7
Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.贝加西他(GSI-953):一种新型的、选择性的噻吩磺酰胺类淀粉样前体蛋白γ-分泌酶抑制剂,用于治疗阿尔茨海默病。
J Pharmacol Exp Ther. 2009 Nov;331(2):598-608. doi: 10.1124/jpet.109.152975. Epub 2009 Aug 11.
8
In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.体内β-分泌酶1抑制导致脑内β淀粉样蛋白水平降低,淀粉样前体蛋白的α-分泌酶加工增加,而对神经调节蛋白-1无影响。
J Pharmacol Exp Ther. 2008 Mar;324(3):957-69. doi: 10.1124/jpet.107.130039. Epub 2007 Dec 21.
9
Inhibition of amyloid beta-peptide production by blockage of beta-secretase cleavage site of amyloid precursor protein.通过阻断淀粉样前体蛋白的β-分泌酶切割位点来抑制β-淀粉样肽的产生。
J Neurochem. 2007 Jun;101(6):1583-95. doi: 10.1111/j.1471-4159.2006.04441.x.
10
Identification of beta-secretase-like activity using a mass spectrometry-based assay system.使用基于质谱的检测系统鉴定β-分泌酶样活性。
Nat Biotechnol. 2000 Jan;18(1):66-70. doi: 10.1038/71944.

引用本文的文献

1
Peptide-Drug Conjugates: An Emerging Direction for the Next Generation of Peptide Therapeutics.肽药物偶联物:下一代肽治疗药物的新兴方向。
J Med Chem. 2024 Feb 8;67(3):1641-1661. doi: 10.1021/acs.jmedchem.3c01835. Epub 2024 Jan 26.
2
Peptide-Drug Conjugates: A New Hope for Cancer Management.肽药物偶联物:癌症管理的新希望。
Molecules. 2022 Oct 25;27(21):7232. doi: 10.3390/molecules27217232.
3
ConjuPepDB: a database of peptide-drug conjugates.ConjuPepDB:一个肽类药物偶联物数据库。
Nucleic Acids Res. 2021 Jan 8;49(D1):D1102-D1112. doi: 10.1093/nar/gkaa950.
4
Pharmacological Inhibition of Amyloidogenic APP Processing and Knock-Down of APP in Primary Human Macrophages Impairs the Secretion of Cytokines.药物抑制淀粉样前体蛋白(APP)的生成及敲低原代人巨噬细胞中的 APP 表达均会损害细胞因子的分泌。
Front Immunol. 2020 Sep 3;11:1967. doi: 10.3389/fimmu.2020.01967. eCollection 2020.
5
Insights into the Impact of a Membrane-Anchoring Moiety on the Biological Activities of Bivalent Compounds As Potential Neuroprotectants for Alzheimer's Disease.洞察膜锚定部分对二价化合物生物活性的影响,这些化合物可能是阿尔茨海默病的神经保护剂。
J Med Chem. 2018 Feb 8;61(3):777-790. doi: 10.1021/acs.jmedchem.7b01284. Epub 2018 Jan 5.
6
The Metalloprotease Meprin β Is an Alternative β-Secretase of APP.金属蛋白酶Meprinβ是淀粉样前体蛋白(APP)的另一种β-分泌酶。
Front Mol Neurosci. 2017 Jan 5;9:159. doi: 10.3389/fnmol.2016.00159. eCollection 2016.
7
Solid-Phase Synthesis and Characterization of N-Terminally Elongated Aβ-3-x -Peptides.N端延长的Aβ-3-x肽的固相合成与表征
Chemistry. 2016 Jun 13;22(25):8685-93. doi: 10.1002/chem.201600892. Epub 2016 May 11.
8
Generation of aggregation prone N-terminally truncated amyloid β peptides by meprin β depends on the sequence specificity at the cleavage site.膜型基质金属蛋白酶β(meprin β)生成易于聚集的N端截短型淀粉样β肽取决于切割位点的序列特异性。
Mol Neurodegener. 2016 Feb 19;11:19. doi: 10.1186/s13024-016-0084-5.
9
Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease.将淀粉样蛋白级联假说聚焦于N端截短的β-淀粉样肽,作为治疗阿尔茨海默病的药物靶点。
Acta Neuropathol. 2014;127(6):787-801. doi: 10.1007/s00401-014-1287-x. Epub 2014 May 7.
10
Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.脑焦谷氨酸淀粉样蛋白β由组织蛋白酶B产生,并被半胱氨酸蛋白酶抑制剂E64d所降低,这代表了一种潜在的阿尔茨海默病治疗方法。
J Alzheimers Dis. 2014;41(1):129-49. doi: 10.3233/JAD-131370.